A number of oncogenes alter the regulation of the cell cycle and cell death, contributing to the altered growth of tumours.
Introduction
A number of cell lines and primary cells of mesenchymal origin become quiescent when deprived of growth factors or matrix interactions. Even in the absence of both conditions such quiescent cells remain viable for some time. 1 ± 3 In contrast, the same cells transformed by either polyomavirus or RSV (Rous sarcoma virus) do not enter viable quiescence when denied both serum growth factors and matrix; they either multiply in suspension or become non-viable, a phenomenon that permitted the selective isolation of revertants of polyomavirus transformed cells and of ts (temperature sensitive) transformation mutants of RSV. 2, 3 We recently characterised how v-Src, the oncoprotein of RSV, prevented withdrawal from the cell cycle in the absence of growth factors 4 and we now wish to understand how v-Src influences viability in these non-quiescent cells.
Several oncoproteins can induce the paradoxical outcomes of cell multiplication and senescence or apoptosis, depending on the cellular context. 5 For example c-Myc, E2F-1 and v-Jun induce both cell proliferation and apoptosis 6 ± 8 whilst Ras, operating through the Raf pathway has similar effects. 9 However, Ras stimulation of PI3-K protects against apoptosis 9 and this is thought to be a reason why Ras and other anti-apoptotic oncogenes such as Bcl-2 demonstrate oncogenic cooperation with cMyc, 10 ± 12 each oncogene countering the other's antiproliferative properties.
The way in which oncoproteins such as Myc and E2F-1 induce apoptosis is beginning to be characterised. 13, 14 vSrc transformation stimulates c-Myc expression 15, 16 suggesting a likely pro-apoptotic effect. However v-Src can also activate several kinases which can inhibit cell death including ERK 17, 18 and PI3-K 19 which induces cell survival in epithelial cells following detachment via the downstream serine/threonine kinase, Akt. 20 This suggests that v-Src may promote cell death or protect from cell death under different conditions.
We made use of Rat-1 cells transformed by a temperature sensitive v-Src (ts LA 29) which we used previously to characterise the mitogenic effects of v-Src. 4, 18, 21 Here we use the reversibility of ts v-Src to examine the effect of inactivating v-Src in transformed cells grown under low serum conditions. We found that the cells exited the cell cycle and were committed to a programme of cell death. We characterised the death as apoptosis by morphological changes including membrane blebbing, DNA and nuclear fragmentation and biochemical changes including the activation of caspases 22 and the activation of the stress induced kinases, JNK and p38. 23 ± 25 Over expression of the anti-apoptotic protein Bcl-2 26 prevented cell death and treatment with the caspase inhibitor Z-VAD-FMK 27 and the p38 inhibitor SB203580 28 simultaneously but not independently significantly reduced cell death. This suggested that the apoptotic pathway required either caspases or p38 and interacted functionally with Bcl-2.
Since v-Src transformed cells did not undergo apoptosis when v-Src was active we assessed whether apoptosis seen when v-Src was switched off was due to loss of v-Src survival signals. We investigated the effect of switching off v-Src on PI3-K and ERK activity and found that ERK and Akt (which is activated downstream of PI3-K) were rapidly inactivated. We tested whether inactivation of either kinase could induce cell death in v-Src transformed cell using LY294002 to inhibit PI3-K 29 and PD98059 to inhibit ERK activating kinase (MEK1). 30 We found that LY294002 was sufficient to induce apoptosis when added to v-Src transformed cells in low serum but did not induce apoptosis when added to normal Rat-1 cells grown under low serum conditions. This suggests that, in the absence of serum survival signals, v-Src promotes apoptosis but the transformed cells are protected from cell death by survival signals from v-Src mediated by PI3-K which could explain why v-Src does not require a co-operating oncoprotein. We suggest that the anti-apoptotic effects of v-Src could be as important to the transforming ability of the v-Src oncoprotein as the effects on mitogenesis.
Results v-Src activity prevents transformed cells undergoing apoptosis in low serum
Rat-1 cells expressing the ts LA 29 v-Src mutant of RSV (ts LA 29 Rat-1) are transformed at the permissive temperature for v-Src activity (358C) and morphologically normal at restrictive temperature (39.58C). When such cells were placed in 0.2% serum medium (low serum) for 24 h they continue to cycle at 358C ( Figure 1A , 0 h and 4 ). On inactivating v-Src by shift to 39.58C we used flow cytometry to show that there was the expected rapid reduction in the number of cells in S-phase (as judged by the number of cells which incorporated BrdU during a 1 h pulse, Figure 1A , 4 and 8 h). The same phenomenon is seen initially when v-Src is inactivated in the presence of serum growth factors. 4 In contrast to the cells' behaviour in high serum, however, v-Src inactivation in low serum led to many cells becoming loosely adherent (detached) within a few hours, with rounded or blebbing morphology ( Figure 1B ) and fragmented nuclei ( Figure 1C ) which could be labelled using the TUNEL (TdTmediated dUTP nick end labelling) technique 31 ( Figure 1D ).
Almost all cells had detached in this way by 24 h after v-Src inactivation. When detached and still adherent cells were harvested separately 8 h after inactivating v-Src in low serum, flow cytometry showed the detached cells to have a peak DNA content less than the G 0 /G 1 peak (Figure 1E , left) and a smaller cell size ( Figure 1E, right) . The still adherent cells were smaller than cells in which v-Src was active ( Figure  1E ) but not as small as the detached cells. DNA isolated from detached and adherent cells separated into 200 base pair ladders, again the adherent cells had an intermediate phenotype with the laddering being more apparent in the detached cell DNA ( Figure 1F ). Thus inactivation of v-Src in transformed cells which lack serum survival factors led to the rapid onset of changes characteristic of apoptosis; cell shrinkage, blebbing and detachment, nuclear fragmentation, TUNEL labelling and DNA laddering. These changes could be prevented by replacing serum up to 2 h after inactivating v-Src but from 4 h after v-Src inactivation, the cells were progressively committed to a programme of cell death ( Figure 1G ) that eventually involved the whole population. Our results indicate that v-Src protected from cell death under low serum conditions but cells became committed to death when v-Src was switched off. Thus under low serum conditions survival signals from v-Src prevent commitment to death in v-Src transformed cells.
Biochemical changes associated with apoptosis induced by switching off v-Src
Apoptosis is frequently associated with activation of specific proteases, caspases and with the activation of the stress activated kinases p38 and JNK. Using a biotinylated peptide, which binds to the large subunits of all active caspases tested, 32 we detected active caspases in extracts from cells harvested 2.5 h after v-Src inactivation ( Figure 2A ). All members of the MAP kinase family including JNK and p38 are activated by dual tyrosine, serine/threonine phosphorylation in the catalytic domain by specific MAP kinase kinases. 33 We used antibodies specific for the dual Thr183/ Tyr185 form of JNK or Thr180/Tyr182 form of p38 to determine the amount of active p38 and JNK. We detected phosphorylated p38 and JNK 4 h after v-Src inactivation ( Figure 2B ). This was due to switching off v-Src and not to the change in temperature since no increase in p38 or JNK phosphorylation was seen in Rat-1 cells grown in low serum for 24 h at 358C and shifted to 39.58C (not shown). Several different isoforms of JNK have been reported around 54 and 46 kD which are produced from three JNK genes by alternative spicing. 34 We found an isoform of JNK in apoptotic cells whose appearance correlated with a decrease in the amount of p54 JNK ( Figure 2B ), suggesting that it might be derived from the p54 isoform. We could also detect two JNK isoforms around 45 kD. Thus activation of caspases, JNK and p38 and the appearance of morphological changes characteristic of apoptosis ( Figure 1 ) were all initiated between 2 and 4 h after inactivating v-Src.
Activation of JNK and p38 can be triggered by caspases which, in some cell types, cleave and activate two upstream kinases, MEKK1 and PAK-2 (p21-activated kinase-2). 35, 36 Since caspases JNK and p38 were activated simultaneously ( Figure 2A and B), we investigated whether caspase activity was required for the activation of JNK or p38. We added a general caspase inhibitor Z-VAD-FMK 27,37 1 h before switching off v-Src and harvested the adherent and detached cells separately after 6 h. Treatment with Z-VAD-FMK prevented the cleavage of two known caspase substrates FAK (data not shown) and p27 ( Figure 3A) , 38 indicating that caspase activity was inhibited. We found that Z-VAD-FMK slightly reduced the amount of active JNK compared to total JNK in detached cells but increased the amount of active JNK in the adherent cells ( Figure 3B ). More markedly, Z-VAD-FMK reduced active p38 in adherent cells and almost abolished it in detached cells ( Figure 3C ). This suggests that during apoptosis initiated by switching off v-Src under low serum conditions, the activation of p38 was largely dependent on the activation of caspases, while activation of JNK was not.
The new form of JNK ( Figure 3B , arrows) was present in extracts from control detached cells but not in extracts from Z-VAD-FMK treated detached cells, which also retained the p54 isoform of JNK. The general caspase inhibitor Boc-D-FMK also inhibited the formation of the new JNK isoform, which suggests that the new isoform could have been formed by caspase cleavage of p54 JNK. The p54 isoform has a longer C-terminal tail, 34 not present in p46 JNK, which could be the location of the cleavage site.
The role of caspases and p38 in apoptosis
Since we found that activation of caspases 2.5 h after switching off v-Src (Figure 2A ), correlated with commitment to cell death ( Figure 1G ), we investigated whether inhibiting caspases would prevent cell death. We found that the caspase inhibitor Z-VAD-FMK, added at the same time as inactivating v-Src, reduced cell shrinkage in the detached cells ( Figure 4A , right panels) but did not prevent cell detachment or membrane blebbing ( Figure 4B Figures 1B  and 4B ). This suggests that caspases were not required for cell death but are required for cell shrinkage and the cessation of cell blebbing. Previous work has shown that cell blebbing in the presence of Z-VAD-FMK requires the activity of p38. 24 Cells treated with Z-VAD-FMK retained some p38 activity ( Figure  3C ) raising the possibility that signalling through p38 was sufficient to induce blebbing and cell death. We added a selective inhibitor of p38, SB203580 28 at the same time as inactivating v-Src and investigated the effect on cell blebbing and TUNEL labelling. We found that SB203580 had no effect on the number of cells undergoing cell blebbing (data not shown) and no significant effect on the number of TUNEL positive cells ( Figure 4E ). However, when we added both Z-VAD-FMK and SB203580 we observed a 65% drop in the number of TUNEL positive cells ( Figure 4E ) and a similar fall in the number of cells undergoing cell blebbing (data not shown). Thus, in order to prevent cell death it was necessary to block both caspases and p38 suggesting that either was sufficient to induce cell death under these conditions. Therefore, we investigated the effect of switching off v-Src on the activities of PI3-K and ERK using antibodies specific for phospho Ser473 Akt and phospho p44/42 ERK. Akt phosphorylation is a good indicator of PI3-K activity since it is recruited to the membrane by the phospholipid products of PI3-K where it is activated by phosphorylation at Thr308 and Ser473. 39 ERK is activated by phosphorylation on Thr202/ Tyr204 by MEK1. 33 We found a rapid decline in the activated Akt and ERK after switching off v-Src ( Figure 5A ). The upper band detected with the phospho-ERK antibody at 0 h did not appear in all experiments and its identity is not known. ERK phosphorylation returned at 4 h, simultaneous with the phosphorylation of p38 and JNK ( Figure 2C ) and the onset of apoptosis, whereas Akt protein was down regulated from 4 h consistent with cleavage by caspases as reported by Widmann et al. 40 . The decline in ERK and Akt phosphorylation was due to switching off v-Src and not to the increase in temperature from 35 to 39.58C as this was not seen in extracts from Rat-1 cells grown in low serum for 24 h at 358C then shifted to 39.58C (not shown). Since both the ERK and PI3-K were rapidly inactivated when v-Src was switched off, this showed that both were controlled by v-Src activity in ts LA 29 Rat-1 cells and are candidate mediators of v-Src induced survival signals.
To test whether either pathway relayed v-Src induced survival signals we used PD98059, a specific inhibitor of MEK1, 30 to inactivate ERK or LY294002, a specific inhibitor of PI3-K. 29 We cultured v-Src transformed cells for 24 h in low serum conditions then added LY294002 or PD98059 and assessed the effect on phosphorylation of Akt or ERK by immunoblotting and on cell survival by TUNEL. We found that PD98059 reduced ERK phosphorylation ( Figure  5B ) and LY294002 reduced Akt phosphorylation ( Figure   Figure 6 . However, whereas LY294002 induced apoptosis, PD98059 did not induce apoptosis, nor did it increase the amount of apoptosis induced by LY294002 when the two inhibitors were added together ( Figure 5D ). Importantly, we found that the induction of apoptosis by LY294002 in low serum conditions were specific to v-Src transformed cells. ts LA 29 Rat-1 cells are morphologically normal when grown at the restrictive temperature for v-Src (39.58C). We grew ts LA 29 Rat-1 cells in normal growth medium at 39.58C for several days or normal Rat-1 cells at either 35 or 39.58C. After incubation in low serum for 24 h we added LY294002 and found no increase in TUNEL labelling after 6 h ( Figure 5E ). This suggests that the requirement for survival signals mediated by PI3-K activity is a characteristic of v-Src transformed cells incubated under low serum conditions.
If PI3-K is responsible for mediating v-Src survival signals we would expect that death induced by inhibiting PI3-K would be mediated by the same pathway as death induced by switching off v-Src. To investigate this we harvested adherent and detached cells treated with LY294002 to examine the appearance of the new isoform of JNK, which we showed was dependent on caspase activity ( Figure 3A ) and the activation of p38 and JNK. Cells treated with PD98059 (most of which remained attached) served as a control. Treatment of serum deprived v-Src transformed cells with LY294002 induced p38 and JNK phosphorylation and the new isoform of JNK in the detached cells, whereas PD98059 had no effect ( Figure 5F ). In contrast to results shown in Figures 2B and  3B , we did not see any active p38 in the adherent cells in Figure 5F , suggesting that cells with active p38 were weakly attached and could be harvested with detached cells. These results indicate that apoptosis induced by inhibiting PI3-K under low serum conditions is accompanied by similar biochemical events to that induced by switching off v-Src, supporting the role for PI3-K in mediating v-Src survival signals.
Cell death is inhibited by the anti-apoptotic protein Bcl-2
Over expression of Bcl-2 or Bcl-X L can inhibit some but not all types of apoptosis.
41,42 Therefore we tested whether over expression of Bcl-2 would inhibit cell death induced by switching off v-Src. We transfected ts LA 29 Rat-1 cells with a mammalian expression vector for mouse Bcl-2 and isolated clones which over express Bcl-2 to differing extents ( Figure  6A ). We found that Bcl-2 inhibited cell death induced by v-Src inactivation or by LY294002 in a dose-dependent manner (TUNEL labelling shown in Figure 6B ). However, Bcl-2 did not block the fall in Akt or ERK phosphorylation after v-Src was switched off ( Figure 6C ). These results show that Bcl-2 blocks cell death due to switching off v-Src or inhibiting PI3-K without blocking inactivation of Akt.
The Bcl-2 family of anti-apoptotic proteins inhibit apoptosis by preventing activation of caspases, JNK and p38. 26,41,43 ± 45 Our results suggest that Bcl-2 blocked cell death downstream of Akt, thus to define more precisely where Bcl-2 acted we determined if it could inhibit phosphorylation of JNK and p38 or the caspase dependent mobility shift in JNK. JNK and p38 did not become phosphorylated in clones expressing high levels of Bcl-2 whereas they were phosphorylated in clones containing the plasmid alone ( Figure 6D) . Similarly, the new JNK isoform (indicted by arrows) was not seen in clones with high Bcl-2 levels ( Figure 6D ). These results suggest that Bcl-2 blocks cell death upstream of the activation of caspases, JNK and p38 and downstream of PI3-K and Akt.
Discussion
The apoptotic activities resulting from the activation of mitogenic oncoproteins may protect normal cells from unscheduled proliferation, and this is one postulated reason for co-operation between mitogenic and anti-apoptotic oncogenes. 10 ± 12 Unlike other oncoproteins, the deregulated tyrosine kinase v-Src does not require a co-operating partner to induce full neoplastic transformation, however, as a potent mitogen, v-Src might also be expected to promote apoptosis. If so, then v-Src itself must induce a countervailing antiapoptotic process if it is to succeed in inducing neoplasia on its own. We show here that v-Src does indeed induce both pro-apoptotic and anti-apoptotic effects in Rat-1 cells cultured with insufficient serum survival factors.
The potentially deleterious effect of v-Src on cell viability was implied in very early studies, which showed that, in low serum, v-Src expressing cells either multiplied or died, but could not become quiescent. 3 We demonstrate here that vSrc transformed cells in low serum are primed to die by apoptosis when v-Src is switched off (Figure 1 ) or PI3-K is inhibited ( Figure 5D ). Apoptosis was specific to v-Src transformed cells in low serum, since inhibition of PI3-K in low serum did not lead to apoptosis in normal Rat-1 cells or ts LA 29 Rat-1 cells in which v-Src had been inactive for several days ( Figure 5E ). Since ts LA 29 Rat-1 cells display this apoptosis upon switching off v-Src in low serum, either the oncoprotein or serum must provide an overriding survival signal ( Figure 1G ). The speed and magnitude of the apoptotic response in this conditional system may make it useful for studying details of apoptotic commitment and execution. We, however, have concentrated on the dual roles of v-Src in this phenomenon and their consequences for Src biology.
Possible mechanisms of priming apoptosis by v-Src under low serum conditions
A proapoptotic effect of v-Src in low serum has not been previously described and, although we do not know how it is mediated, the properties of v-Src offer several interrelated possibilities.
Firstly, v-Src upregulates c-Myc, which has been shown both to promote cell proliferation and to prime Rat-1 cells for apoptosis under low serum conditions (comprehensively reviewed in 46 ). Secondly, there is evidence that activated Ras promotes apoptosis through Raf signalling 9 and v-Src also activates this pathway. 18 Thirdly, v-Src disrupts cell cycle controls 4, 18, 21 and the ability to induce apoptosis under low serum conditions, common to mitotic oncopro-teins such as E2F-1, 6,47 v-Jun 8 and c-Myc, 7 could be a consequence of deregulated cell cycle progression. Variations of the dual signal model for Myc function postulate that the oncogene coordinately stimulates distinct pathways for apoptosis and proliferation. 46 v-Src may also show this functional duality since addition of the MEK1 inhibitor, PD98059, throughout the 24 h incubation in low serum arrested v-Src transformed Rat-1 in G 0 /G 1 but did not prevent apoptosis when v-Src was switched off (data not shown).
Finally, v-Src phosphorylation leads to disruption and turnover of the components of cellular adhesions and linking cytoskeletal elements, 48 a process that became more pronounced during the 24 h incubation in low serum employed in our experiments (data not shown). The consequent attenuation of integrin signalling may be a signal for apoptosis, analogous to detachment induced cell death (`anoikis') in epithelial cells. 49 Serum-deprived mesenchymal cells can survive in the absence of integrin signalling 1 ± 3 and ts LA29 Rat-1 cells at the restrictive temperature and normal Rat-1, which both have a normal morphology, resist apoptosis following PI3-K inhibition ( Figure 5E ). This implies that, in mesenchymal cells, either integrin mediated or other signals are sufficient to induce survival. These signals can substitute for one another since we showed previously that surrogate integrin signalling can protect serum-deprived fibroblasts from Myc-induced apoptosis. 50 In serum-deprived ts LA29 Rat-1 cells at the permissive temperature inactivation of v-Src or inhibition of PI3-K may remove another survival signal from cells whose integrin survival signalling has been disrupted by morphological transformation, resulting in the onset of cell death.
v-Src induced survival signals
We showed that the v-Src survival signal is mediated, at least in part, by PI3-K, since the PI3-K inhibitor, LY294002, induced significant apoptosis in v-Src transformed cells grown under low serum conditions ( Figure 5D ). v-Src can bind and activate PI3-K 19 and, when we switched off v-Src, we observed inactivation of PI3-K, as evidenced by reduced Akt phosphorylation ( Figure 5A ). Furthermore, LY294002 inhibited Akt phosphorylation, showing that this inhibitor did, indeed, act on the PI3-K pathway ( Figure 5C ). Taken together, these results show that v-Src survival signals mediated by PI3-K protect cells from v-Src-primed apoptosis. Previous reports showed that v-Src survival signals mediated by PI3-K protected epithelial cells from anoikis 51 and Rat-1 cells from UV induced apoptosis, 52 suggesting that this is a general mechanism whereby v-Src can provide a survival signal to protect against different apoptotic stimuli.
The effectors of v-Src primed apoptosis
Survival signals mediated by Akt have been shown to impinge on the apoptotic machinery in a number of ways including phosphorylation of Bad (Bcl-XL/Bcl-2 associated death factor) 53 and pro-caspase 9. 54 Phosphorylation prevents pro-caspase 9 activation while phosphorylated Bad is held within the cytosol in a complex with 14-3-3 protein. 53, 55 When
Akt is inactivated Bad is dephosphorylated and moves to the mitochondrial membranes where it may titrate out the antiapoptotic Bcl-2 family members. This may allow pro-apoptotic Bcl-2 family members to homodimerize and interact with pores in the mitochondrial membranes, resulting in release AIF 56 and cytochrome c 26 which in turn activates caspase 9. Thus dephosphorylation of Bad and/or caspase 9 provides a possible mechanism of both caspase activation and its inhibition by Bcl-2 when v-Src or PI3-K was switched off. Consistent with this we have found that ts LA29 Rat-1 cells express Bad protein (D Johnson and C Dive unpublished).
Additional mechanisms are required to explain why apoptosis induced by switching off v-Src or inhibiting PI3-K was simultaneous with the activation of both caspases and stress activated kinases, JNK and p38 (Figure 2) . Either caspases or p38 were sufficient to induce cell death, although not necessarily all the stigmata of apoptosis, but inhibiting both enhanced cell survival (Figure 4) . In addition the activation of p38 was partly caspase dependent ( Figure  3B ) which may be due to the cleavage and activation of an upstream kinase analogous to cleavage of PAK 2 36 or MEKK1. 35 Therefore switching off v-Src or inhibiting PI3-K engaged at least two independent pathways. These are similar to those reported downstream of Fas 45, 47 since ligation of Fas or other death receptors activated the p38 and JNK pathways 58 ± 61 and independently stimulated the activation of caspase 8. 57 Ras induced PI3-K activity down regulated Fas expression. 62 If v-Src induced PI3-K activity has a similar effect, then switching off v-Src or inhibiting PI3-K would increase Fas expression, which may activate the Fas pathway. Bcl-2 can inhibit Fas induced cell death in some cells and can inhibit activation of JNK 45 and caspase 8 41 at the cell membrane. We found that Bcl-2 inhibited the activation of JNK, p38 and caspases when vSrc or PI3-K were switched off in low serum. If inhibiting PI3-K in ts LA 29 Rat-1 cells in low serum induced Fas expression then Bcl-2 may prevent cell death by blocking JNK, p38 and caspase activation downstream of Fas.
Conclusions
v-Src can both prime for apoptosis and protect against it. Apoptosis priming is not unique to ts LA29 Rat-1, since we observed it also in v-Src transformed chick embryo fibroblasts but not in transformed NIH3T3 cells (data not shown). Proand anti-apoptotic functions are also shown by activated Ras 9 v-Src and Ras share, at least in part, the same anti-apoptotic pathway. However, Ras, unlike v-Src, requires cooperating oncogenes for primary cell transformation, in which its proapoptotic function prevails over the anti-apoptotic effect. With v-Src, the priming for apoptosis is only apparent when serum survival factors are limiting, conditions under which v-Src transformed cells are finely balanced between proliferation and death. These phenomena may, nonetheless, have implications for a role for Src in neoplasia. Many tumours, particularly those of the colon, have high levels of c-Src expression 63, 64 and a few metastatic colon tumours have mutated c-Src which could be important in tumour progression. 65 We showed previously how v-Src induces transformation via effects on cell growth and behaviour. 4, 18, 21, 66 Here we suggest that the ability to induce cell survival could be an equally important transforming activity of v-Src and could be another mechanism whereby deregulated c-Src contributes to tumour formation in vivo. Manipulating pathways involved in the alternative death priming effects of v-Src could have therapeutic potential, therefore it would be interesting to characterise these pathways in v-Src transformed Rat-1 cells.
Materials and Methods
Cell culture and induction of cell death
Rat-1 cells and ts LA 29 Rat-1 cells were maintained as in Johnson et al. 4 BrdU (bromodeoxyuridine) incorporation and labelling was as in Johnson et al. 4 For the induction of cell death, cells were seeded at 1.5610 6 per 90 mm plate, the following day the medium was replaced with medium containing 0.2% serum. After 24 h they were either shifted to restrictive temperature (39.58C) to inactivate v-Src or various inhibitors were added.
To harvest adherent and detached cells we seeded 6610 6 cells on a 150 mm plate. The following day the medium was replaced with medium containing 0.2% serum. After 24 h they were shifted to 39.58C for 6 ± 8 h. The detached cells were harvested by washing carefully and the adherent cells were either harvested by trypsinization or lysed on the plate.
BrdU immunostaining, propidium iodide staining and¯ow cytometry
As in Johnson et al. 4 Generation of cell lines which over express Bcl-2 pSFFV-Bcl-2 expression plasmid was from Stanley J Korsmeyer, Washington University, St Louis, Missouri, USA. ts LA 29 Rat-1 cells were transfected with pSFFV-Bcl-2 or pSFFV using DOTAP (Boehringer Mannheim). Single G418 resistant colonies were isolated, grown up and tested for expression of Bcl-2 by immunoblotting. All colonies isolated from cells transfected with pSFFV-Bcl-2 expressed Bcl-2 but we could not detect Bcl-2 in colonies from cells transfected with pSFFV.
Western blot analysis
As in Johnson et al. 4 except phospho-specific antibodies were used as recommended by the manufacturers.
Antibodies
Phospho-specific antibodies to Akt, JNK and p38 were from New England Biolabs (#9271S, #9251L, #9211S), phospho-ERK was from Promega (#V8031). Total JNK antibody, raised against full-length recombinant JNK was a gift from Billy Clark, Beatson Institute, Glasgow and the p42 ERK antibody, raised against a peptide from the C-terminus of p42 ERK (EETARFQPGYRS), 67 was a gift from Anne Wyke, Beatson Institute, Glasgow. Bcl-2 antibody was from Pharmingen (#15021A), p27 antibody was kind gift of Steve Coats, Amgen, CA, USA.
Inhibitors
Inhibitors were purchased from CalBiochem. Stocks were made in DMSO (dimethylsulphoxide) as follows: Z-VAD-FMK 10 mM stock, used at 100 mM, SB203580 66 mM stock, used at 50 mM, LY294002 80 mM stock, used at 50 mM, PD98059 10 mM stock used at 50 mM.
DAPI (4',6-Diamidino-2-pheylindole) staining
Cells were grown in chamber slides, 1610 4 cells per chamber in 0.4 ml culture medium. They were washed twice in PBS (phosphate buffered saline) then fixed in 3.7% formaldehyde in PBS for 10 min. They were washed in PBS and permeabilised in 0.5% Triton-X-100, 1% BSA in PBS for 30 min. They were washed once in PBS then mounted in Vectashield (Vector Labs) containing 0.1 mg/ml DAPI.
DNA laddering
Cells were harvested by trypsinization, washed in PBS then suspended in TNE (10 mM Tris-Cl pH 8.2, 400 mM NaCl, 2 mM EDTA (ethylenediaminetetraacetic acid)) at a concentration of 5610 6 per ml. Cells were lysed by addition of 0.5% SDS and proteins digested by adding 0.25 mg/ml proteinase K and incubating at 378C overnight. The lysates were extracted with water saturated phenol then chloroform and precipitated with 1.5 volumes of 100% ethanol and spun for 5 min in a microfuge. After a 70% ethanol wash the pellet was dissolved in 100 ml 10 mM Tris pH 8.0, 1 mM EDTA and 0.1 mg/ ml DNase free RNase A was added. Tubes were incubated at 378C for 30 min then 5 ± 10 mg was run on a 2% agarose gel.
TUNEL 31
Cells were harvested and washed once in PBS. They were fixed for 15 min on ice in 1% formaldehyde in PBS then centrifuged at 1000 r.p.m. for 5 min. They were resuspended in 100 ml PBS and 1 ml ice cold 70% ethanol was added. They were stored overnight at 48C and the next day they were rehydrated in PBS on ice for 30 min. Aliquots of 10 6 cells were spun and resuspended in 0.2 M potassium cacodylate, 2.5 mM Tris-HCl pH 6.6, 2.5 mM CoCl 2 , 0.25 mg/ml, BSA, 5 units of TdT (terminal deoxynucleotidyl transferase) and 0.5 nmoles of biotinylated dUTP per tube. They were incubated at 378C for 30 min, washed in 1 ml of PBS then spun and resuspended in 100 ml 46SSC (16SSC=0.15 M NaCl, 0.015 M NaCitrate), 0.1% Triton X-100, 5% low fat dried milk and 5 mg/ml avidin-FITC (fluorescein isothiocyanate). They were incubated for 30 min at room temperature in the dark then washed by addition of 1 ml PBS containing 0.1% Triton X-100, spun and resuspended in 500 ml of PBs containing 10 mg/ml propidium iodide. They were analyzed by flow cytometry and the percentage TUNEL positive cells determined by FITC fluorescence.
Detection of active caspases 32
Cells were lysed by freezing on dry ice and thawing at 378C three times then incubated with Z-EK(bio)D-amok (N-(N a -benzyloxycarbonylglutamyl-N e -biotinyllysyl)aspartic acid[(2,6-dimethylbenzoyl)oxy] methyl ketone) (1 mM added from a 25 mM stock in DMSO) at 378C for 15 min. They were diluted with 26SDS sample buffer, boiled for 3 min and sonicated briefly. They were subject to SDS ± PAGE (polyacrylamide gel electrophoresis) on 16% gels, transferred to nitrocellulose, probed with peroxidase-labeled streptavidin and visualised using ECL (enhanced chemiluminescence). 
